Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to Gordon Research Seminar & Conference “Barriers of the CNS” which will take place in New London, NH, USA, on June 11-17, 2022. Dr. Lemarchant will present results showing that Axoltis’ peptide NX210c reinforces the integrity of blood-CNS barriers in vitro, which may represent an innovative therapeutic strategy to improve outcomes for patients with neurological pathologies. A study performed in collaboration with the lab of Pr. Matthew Campbell (Trinity College Dublin – Ireland).

Axoltis Pharma is delighted to be a contributor to this Gordon Research Conference !

https://www.grc.org/barriers-of-the-cns-conference/2022/